Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,562 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TBP-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

NCT00791778
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

NCT00259376
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

NCT03023891
View directory record Official record
Conditions
Glucocorticoids Toxicity, Glucose Intolerance
Interventions
Prednisone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

NCT00449774
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine IR tablets, Lamotrigine ODT tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Results available

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

NCT01560780
View directory record Official record
Conditions
Coronary Artery Bypass
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 2, 2026, 9:13 PM EDT
Recruiting Phase 2 Interventional

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115
Drug
Lead sponsor
David Reardon, MD
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 9:13 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

NCT03828448
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 2, 2026, 9:13 PM EDT
Terminated Phase 2 Interventional

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT05629208
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Edecesertib, Edecesertib Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 9:13 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery

NCT03956017
View directory record Official record
Conditions
Myocardial Injury
Interventions
Ubiquinone, Placebo
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 2, 2026, 9:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00481091
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

NCT00995410
View directory record Official record
Conditions
Aspirin-Associated Gastric Ulcers
Interventions
PA32540
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 1 Interventional Results available

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

NCT01117623
View directory record Official record
Conditions
Neoplasm
Interventions
Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 2 Interventional

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

NCT06429059
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
Astaxanthin, Protandim, Melatonin, MitoQ
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

NCT01742208
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

NCT04193176
View directory record Official record
Conditions
Chronic Cough
Interventions
Gefapixant, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Paramount, California • Jupiter, Florida • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Early Phase 1 Interventional

Methylprednisolone Treatment of Friedreich Ataxia

NCT02424435
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Methylprednisolone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 2 Interventional Results available

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

NCT04042740
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Glecaprevir/Pibrentasvir (G/P)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 2, 2026, 9:13 PM EDT
Terminated Not applicable Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT03020797
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo Oral Tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 2, 2026, 9:13 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 2, 2026, 9:13 PM EDT